Loading
TAH Stock: price and insider trades · New Zealand
1 insider bought €491k of shares over the last 90 days, the latest filed 30 Sept 2026.
TAH: what insiders have been doing
TAH, classified in the Health Care sector, is a listed company. Its insiders report their share dealings to NZX. The last twelve months, up to 18 October 2026, brought 11 filings signed by 7 insiders.
Not one open-market sale was filed. On the buying side, 1 insider reported 1 purchase totalling €491k. Open-market purchases are the filings investors watch most closely, because the insider pays for the shares out of pocket. Biggest ticket of the year: €491k, bought by Gillon McLachlan and made public on 30 September 2026 (2.2% of market cap). Those buying include 1 senior executive.
Across the 75 companies tracked on its exchange, the median is 4 filings; at 11 filings, this issuer sits above that mark. The full history, which starts in 2026, counts 1 purchase against no sales.
The clock since the last published purchase (30 September 2026) now reads 17 days. The median gap between trade and publication is zero days: most filings appear on the same day. This delay matters because a trade only becomes useful information once it is public.
For comparison within the same sector, see the insider buying recorded at Cooper Companies, Inc. and Cytosorbents Corp. Source: insider filings from NZX. Past trades are no guide to future returns.
Insider Decl.
11
Thresholds
n/a
Buy Volume
€490,813
1 ops. · all time
Sell Volume
n/a
n/a
Who traded when
BuySaleGillon McLachlan1 buy
Since the insiders bought
- +0.9%Entry NZ$4.57 · Close 13 Oct 2026 NZ$4.61
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Fundamental score
Ranked 1,902 of 24,158 companies
75.8
score / 100
Value71
Quality80
FCF yld8.3%
Earn yld6.2%
EV/EBITDA8.8x
ROE65%
Gross mgn50%
Net mgn13%
Debt/EBITDA0.6x
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2026FY ended March 2026 · cache
NZ$4.61
Analyst consensus
Income statement
RevenueNZ$22.5M
Gross profitNZ$11.2M50% margin
EBITDANZ$5.6M25% margin
Net incomeNZ$2.8M12.6% margin
Valuation
PER (trailing)16.5x
P/Book9.1x
Beta-0.11
Balance sheet & cash
Market capNZ$45.9M
Total debtNZ$3.3M
Free Cash FlowNZ$3.8M
Debt / Equity61%
Profitability & ownership
ROE65.3%
ROA23.9%
% insiders82.7%
% institutions0.0%
Last declaration on 8 October 2026
Declarations11 total
878,571 shares@ A$0.912.23% mcap100.0% of flowShareASXASX:2924-03142930-3A703054
Canonical exit: 29 Dec 2026 (T+90)
ShareASXASX:2924-03138848-3A702385
●
ShareASXASX:2924-03119074-3A698394
ShareASXASX:2924-03102001-3A695647
ShareASXASX:2924-03101189-3A695488
Ordinary ShareNZX Main BoardNZX:472685
ShareASXASX:2924-03081398-3A691815
11 of 11 declarations
About TAH
TAH is a company operating in the healthcare and pharmaceutical sector. It is listed on the XNZE market.
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations